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Mouse models of neurological disordersEarly mouse models of neurological disorders emerged 30–40
years ago, generated as mutant strains with affectionate names such
as Teetering, Reeler, Ducky, Weaver, Staggerer, Trembler, Sprawler,
Brindled, to name but a few. The development of molecular biology
techniques from the mid-1980s onwards and the generation of mice
bearing human or mutant human transgenes subsequently trans-
formed our knowledge of many neurological diseases. The aims of
these studies have been fairly straightforward, to understand the
molecular mechanisms behind these diseases, thus leading to
therapeutic strategies and novel drug design. Nevertheless, non-
transgenic models continue to play a signiﬁcant role despite the fact
that they obviously display murine physiology.
This Special Issue of Biochimica et Biophysical Acta addresses
both transgenic and non-transgenic mouse models of human
neurological disorders. A PubMed search for transgenic mouse
models of Alzheimer's disease will show over 2000 publications
since 1990—which is probably not surprising since the disease
forms a major and increasing unmet clinical need. Thus, the topic
undoubtedly forms a signiﬁcant body of the contributions to this
issue.
The issue starts off with a consideration by Harper of how
mutant and transgenic mouse lines have been utilised as model
systems and how mice provide many advantages to other species.
Although “classical” transgenic mice, and speciﬁcally knock-out and
knock-in animals, have provided considerable insights into the
actions of speciﬁc genes, they do have limitations as discussed by
Cazzin and Ring. These authors go on to describe newer models
employing RNAi and viral vectors and how further advances are
being made in our understanding of disease pathogenesis and
pathology. Recent developments in the application of these “newer”
technologies to research into Alzheimer's disease and tauopathies
are described by Jaworski and colleagues.
Non-invasive in vivo assessment of the developing pathology
within any animal model can provide huge bonuses compared to
post-mortem read-outs in terms of observing the changes occurring
in the living animal. Waerzeggers et al. review neuroimaging in
mouse models of neurodegenerative diseases, highlighting the
beneﬁts of imaging in studies involved in the translation from
animal model to man.
The generation of animal models of human diseases is directed
towards two major objectives: (i) facilitating our understanding of
the disease and (ii) developing new therapies. An understanding of
the aetiology of sporadic, non-familial Alzheimer's disease remains
elusive. Lifestyle, including diet, exercise and intellectual stimula-
tion have all been purported to play a role. Schroeder and co-
workers show how dietary manipulation has been explored in
various mouse models with caloric restriction having the potential0925-4439/$ – see front matter © 2010 Published by Elsevier B.V.
doi:10.1016/j.bbadis.2010.08.007to prolong life while a high fat diet and the induction of insulin
resistance has the opposite effect. Transgenic mouse models of
Alzheimer's disease have seen major usage in recent years,
particularly in the discovery and development of active and passive
vaccination approaches based on the generation of antibodies to the
amyloid beta-protein. Despite their initial promise, data derived
from the mouse models conﬂict with ﬁndings emerging from
clinical trials. This approach and the potential for discrepancies
between murine and human studies is described by Wisniewski and
Sigurdsson.
The so-called Alzheimer's mouse, possessing mutated human
transgenes for amyloid precursor protein and presenilin-1, is often
criticised for its lack of tau pathology, an essential pathognomonic
feature of the disease. In the review by Gotz and co-workers, the
modelling of aberrantly phosphorylated tau protein in mice is
compared with that in other species, notably ﬂies and worms and
the relevance of the phosphorylation process as a target for
therapeutic intervention is discussed.
Chuang also assesses the relevance of ﬁndings in Alzheimer's
transgenic mice to the human condition. He describes the data
pointing to altered neurogenesis in such mouse models. Both adult
mouse and human brains possess neural stem cells and these cells
are found in anatomically similar regions in the two species. These
cells also share the ability to generate neurons and are likely to play
a role in learning and memory, functions that compromised in
Alzheimer's disease.
The blood–brain barrier does just what it claims—it provides an
essential barrier and protects the brain from the majority of
bacterial infections and can prevent the access of toxins, such as
botulinum. Dysfunction of the barrier can, however, play a major
role in diseases such as multiple sclerosis and Alzheimer's disease.
In his review, William Banks discusses the blood–brain barrier, its
role in neurological diseases and describes the progress that is being
made with appropriate models.
Mechanisms that might be involved in neurodegenerative
processes are discussed in three reviews. As eluded to earlier,
mouse models generally do not present all of the features of the
human disease, be it Alzheimer's or Parkinson's disease or other.
Nevertheless, the inﬂammatory processes that contribute to such
diseases can be mirrored to a varying extent in mouse models of the
disorder. Schwab et al. discuss how, despite the weaknesses,
particularly in mouse models of Alzheimer's disease, the models
have aided the development of novel therapeutic agents. The topic
of inﬂammation is discussed in greater detail with respect to
cytokines by Campbell and colleagues who provide good evidence
that cytokine-dependent neuroinﬂammatory changes in mice do
model those observed in human neurological disorders. The
784 Prefacemechanisms controlling the neurodegeneration observed after brain
injury are poorly understood. Au et al. describe the process of
autophagy and discuss how acute brain injury can be modelled in
mice and how this is clarifying the role of autophagy in CNS
disorders.
Moving away from neurodegenerative diseases, Colleoni and
Sacerdote review the generation of mouse models of neuropathic
pain. In man, neuropathic pain arises from pathology of the nervous
system associated with conditions such as diabetes and autoimmune
diseases. Although advances in understanding neuropathic pain
mechanisms have been made with classical nerve ligation models,
the authors explain the pros and cons of mimicking clinical pain
conditions in mouse models.
Finally, my thanks to all who have contributed to this Special Issue,
to the authors for their excellent contributions, to the reviewers for
their time and effort and to the editorial staff of Elsevier for their help
in the compiling and production of what I hope is a stimulating
collection of articles.D.R. Howlett
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